Negative allosteric modulator of TrkA has efficacy in pain models

Aug. 9, 2024

Researchers from Alzecure Pharma AB presented preclinical data for ACD-137, a negative allosteric modulator (NAM) of tropomyosin receptor kinase A (TrkA), being developed for the treatment of pain.

BioWorld Science Conferences Neurology/psychiatric Small molecule

Today's news in brief

BioWorld

BioWorld briefs for April 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 10, 2025.

Approved label with medical icons, professional

FDA clears path for Boston Sci’s Bolt IVL to challenge J&J’s Shockwave

BioWorld MedTech

Boston Scientific Corp.’s up to $664 million acquisition of Bolt Medical Inc. closed just days after Bolt secured U.S. FDA 520(k) clearance for its intravascular...

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Remegen’s lupus drug surfaces with phase III myasthenia gravis data

BioWorld

Remegen Co. Ltd. emerged as a surprise challenger in the generalized myasthenia gravis space, unveiling positive phase III data of its China-approved lupus drug,...